What’s the impact of hormone therapy on heart health?

Article

According to a recent study in Annals of Internal Medicine, hormonal therapy in early menopause may improve some markers of cardiovascular disease (CVD) risk, but not progression of atherosclerosis.

 

According to a recent study in Annals of Internal Medicine, hormonal therapy in early menopause may improve some markers of cardiovascular disease (CVD) risk, but not progression of atherosclerosis.

Led by researchers from Phoenix Veterans Affairs Care System, the study included 727 healthy menopausal women aged 42 to 58 years between 6 and 36 months from last menses without prior CVD events. They had coronary artery calcium scores <50 Agatston units and had received no estrogen or lipid-lowering agent for at least 90 days. Randomization was to either oral conjugated equine estrogens (o-CEE), 0.45 mg/d, or transdermal 17β-estradiol (t-E2), 50 mcg/d, each with 200 mg of oral progesterone for 12 days per month, or placebo for 48 months.

More Contemporary OB/GYN news reports on menopause

The annual change in carotid artery intima-media thickness (CIMT) measurement was the primary end point; secondary end points included changes in markers of CVD risk.

Of the participants, 89.3% had at least 1 follow-up CIMT during the study period and 79.8% had CIMT at 48 months. For all groups, the mean CIMT increase was 0.007 mm/y. Across groups, the percentage of participants whose coronary artery calcium score increased also was similar. No effects on blood pressure were seen for either o-CEE or t-E2. With o-CEE, improvements were seen in levels of C-reactive protein, sex hormone-binding globulin, and low- and high-density lipoprotein levels but not in interleukin-6. Decreased insulin resistance was associated with t-E2. No difference in serious adverse events was seen between treatments.

Investigators concluded that despite improving some CVD risk factors, 4 years of early hormonal therapy did not have an effect on atherosclerosis. 


 

 

To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.

Recent Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit: uvahealth.com
Navigating vasomotor symptoms in breast cancer patients | Image Credit: menopausefoundationcanada.ca.
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Hot flashes poorly impact sleep quality | Image Credit: intimmedicine.com
How to manage bone health in midlife women | Image Credit: - endocrine.org
Mary Jane Minkin, MD, discusses The Menopause Society 2023 Annual Meeting | Image Credit: Yale School of Medicine
Highlights from The Menopause Society 2023 Annual Meeting  | Image Credit: nursebarb.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.